Amyl Team at the International Society on Amyloidosis (ISA) 2022.
4-8 September 2022

We are proud to announce that the Amyl team participated in the ISA (International Society on Amyloidosis) 2022 conference, presenting a poster that highlights our latest advancements on amyloidosis disease research. The team had the opportunity to engage with leading scientists and industry experts, sharing our insights and learning from the brightest minds in the field.

For those interested in our work, you can download our poster presentation here. We are excited to continue pushing the boundaries of science and look forward to further discussions sparked by our research.

Connect
Arrow right
About Merieux Equity Partners
Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to  equity investments in healthcare. MxEP actively supports entrepreneurs and companies  with differentiated products and services, giving them privileged access to its sector  expertise and international network. MxEP currently manages c.€1.5bn ($1.6bn) AUM.
About Noshaq Partners
Noshaq is a Belgian investment fund and project developer with a portfolio of 477 companies. Noshaq is the reference financial partner for the creation and development of SMEs in the Liege region (Wallonia). Over the years, it has developed a range of financing vehicles in line with the needs and trends of the market and its strategy. Each service offered by Noshaq (capital – loan – leasing) is always determined according to the demands and needs of the owner-investor. Its objective is always to have a leverage effect on the company’s development.
About Sambrinvest
With over 35 years of experience working alongside companies and entrepreneurs, more than 280 portfolio companies and 170 million euros in assets under management, Sambrinvest is a major venture capital player in Wallonia. More than an investment fund, Sambrinvest is also a catalyst for the development of local ecosystems, such as biotech, digital and engineering.
5.3.24
2024 AD/PD conference
7.11.23
Amyl Therapeutics receives additional €5M funding
4.9.22
Amyl Team at the International Society on amyloidosis